OncoMatch/Clinical Trials/NCT07340489
Serplulimab for Locally Advanced Cervical Cancer
Is NCT07340489 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Serplulimab and Chemotherapy for cervical cancer.
Treatment: Serplulimab · Chemotherapy — This study is a randomized, controlled, open-label, phase II clinical trial designed to enroll patients with previously untreated locally advanced cervical cancer. The study aims to evaluate the efficacy and safety of adding chemotherapy to serplulimab combined with concurrent chemoradiotherapy. The primary endpoint of this study is progression-free survival (PFS).
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Biomarker criteria
Allowed: PD-L1 (CD274) any tested
PD-L1 status not restricted
Disease stage
Required: Stage IIB, III, IVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-tumor treatment
No prior anti-tumor treatment; Prior anti-tumor treatment [excluded]
Lab requirements
Blood counts
ANC ≥ 1.5 × 10⁹/L; Platelet count ≥ 100 × 10⁹/L
Kidney function
Serum creatinine ≤ ULN
Liver function
Total bilirubin, ALT, and AST ≤ 1.5 × ULN
Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; Platelet count ≥ 100 × 10⁹/L; Total bilirubin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ 1.5 × upper limit of normal (ULN); Serum creatinine ≤ upper limit of normal (ULN)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify